慢性肾脏病治疗的新靶点和新药物  

The novel therapeutic targets and treatments for chronic kidney diseases

作　　者：柳晶[1] 季大玺[1] 

机构地区：[1]南京军区南京总医院肾脏科国家肾脏疾病临床医学研究中心全军肾脏病研究所,南京210016

出　　处：《肾脏病与透析肾移植杂志》2015年第2期171-175,共5页Chinese Journal of Nephrology,Dialysis & Transplantation

基　　金：国家科技支撑计划课题(2013BAI09B04)(2015BAI12B05);江苏省临床医学中心项目(BL2012007)

摘　　要：慢性肾脏病(CKD)是全球范围内重要的公共健康问题。在探索CKD分子致病机制的基础上发现新的治疗靶点和药物,对提高CKD诊治水平,延缓疾病进展,改善患者长期预后,减轻政府卫生经济负担具有极其重要的意义。本文总结近年来CKD研究中发现的新的分子致病机制,及针对这些新机制的治疗方法和药物,重点关注了作用于转化生长因子β超家族的抗肾脏纤维化药物,以及血管钙化因子、烟酰胺腺嘌呤二苷酸磷酸(NADPH)过氧化物家族、核因子κB通路等在CKD发生发展中的分子致病机制。Chronic kidney disease （CKD） is becoming a worldwide epidemic. Novel targets and treatments for CKD are, therefore, desperately needed to both mitigate the burden of this disease in the general population and reduce the necessity for renal replacement therapy in individual patients. This review highlights new insights into the mechanisms that contribute to CKD, and approaches that might facilitate the development of disease arresting therapies for CKD. Particular focus is given to therapeutic approaches using antifibrotic agents that target the transforming growth factor β superfamily. In addition, we discuss new insights regarding the roles of vascular calcification, the NADPH oxidase family, and NF-κB pathway in the pathogenesis of CKD. Prospective therapeutics based on these findings will hopefully renew hope for clinicians and patients in the near future.

关 键 词：慢性肾脏病 治疗靶点 治疗药物 

分 类 号：R692[医药卫生—泌尿科学]